Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633893 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL11843358 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9098838 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL7364954 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9097633 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9096777 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9099781 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL9099300 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL7526762 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 | |
| SCHEMBL16330120 | 0.94 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1EPHX2HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | ALDH1A1 3876/4885MAPK1 4662/4885L3MBTL1 326/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | ALDH1A1 3876/4885MAPK1 4662/4885L3MBTL1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.